HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Wang, Pei pei ^a,d   Xie, Dong ying ^a,d   Liang, Xu Jing ^b   Peng, Liang ^a   Zhang, Geng lin ^a   Ye, Yi nong ^c   Xie, Chan ^a,d   Gao, Zhi liang ^a,d  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LUCIFERASE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; SCATTER FACTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CELL ACTIVATION; CELL CONTACT; CELL FUNCTION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LIVER FIBROSIS; MESENCHYMAL STEM CELL; MYD88 GENE; NONHUMAN; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING;

ANIMALS; BONE MARROW CELLS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC STELLATE CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; LIPOPOLYSACCHARIDES; LIVER CIRRHOSIS; MESENCHYMAL STROMAL CELLS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 84865304560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043408     Document Type: Article

References (31)

1. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, et al. (2003) Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 9: 274-276.
2. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, et al. (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 52: 886-893.
3. Baranova A, Lal P, Birerdinc A, Younossi ZM, (2011) Non-Invasive markers for hepatic fibrosis. BMC Gastraenterology 11: 1-15.
4. Soares J-B, Pimentel-Nunes P, Roncon-Albuquerque R Jr, Leite-Moreira A, (2010) The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 4: 659-672.
5. Gaia S, Smedile A, Omedè P, Olivero A, Sanavio F, et al. (2006) Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol 45: 13-19.
6. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, et al. (2006) Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24: 2292-2298.
7. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, et al. (2006) Characterisation and clinical application of human CD34+stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 24: 1822-1830.
8. Baertschiger RM, Serre-Beinier V, Morel P, Bosco D, Peyrou M, et al. (2009) Fibrogenic Potential of Human Multipotent Mesenchymal Stromal Cells in Injured Liver. PLoS One 17: e6657.
9. Sakaida I, Terai S, Nishina H, Okita K, (2005) Developmentof cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol 38: 197-202.
10. Xie C, Zheng YB, Zhu HP, Peng L, Gao ZL, (2009) Human Bone Marrow Mesenchymal Stem Cells are resistant to HBV Infection during differentiation towards Hepatocytes in vivo and vitro. Cell Biology Int 33: 493-500.
11. Schwabe RF, Schnabl B, Kweon YO, Brenner DA, (2001) CD40 activates NF-kB and c-Jun N-terminal kinase and enhances chemokine secretion on acti-vated human hepatic stellate cells. J Immunol 166: 6812-6819.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ, (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520.
13. Wiest R, Garcia-Tsao G, (2005) Bacterial translocation (BT) in cirrhosis. Hepatology 41: 422-433.
14. Nolan JP, Leibowitz AI, (1978) Endotoxin and the liver. III. Modification of acute carbon tetrachloride injury by polymyxin b - an antiendotoxin. Gastroenterology 75: 445-449.
15. Grinko I, Geerts A, Wisse E, (1995) Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J Hepatol 23: 449-458.
16. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, et al. (1995) Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 22: 165-172.
17. Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D, (2005) Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 289: 571-578.
18. Guo J, Loke J, Zheng F, Hong F, Yea S, et al. (2009) Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49: 960-968.
19. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, et al. (2002) Pluripotency of mesenchymal stem cells derived from adut marrow. Nature 418: 41-49.
20. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, et al. (2004) Transplantation of bone marrow cells reduces CCL4-induced liver fibrosis in mice. Hepatology 40: 1304-1311.
21. Oyagi S, Hirose M, Kojima M, Okuyama M, Kawase M, et al. (2006) Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4- injured rats. J Hepatol 44: 742-748.
22. Payne C, Samuel K, Pryde A, (2007) The impact of bone marrow stem cells on liver fibrosis in critically determined by their route of cell trafficking. Hepatology 46: 710A.
23. Sakaida I, Terai S, Nishina H, Okita K, (2005) Developmentof cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol 38: 197-202.
24. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, et al. (2011) Autologous bone mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 54: 820-828.
25. Chen X, Katakowski M, Li Y, Lu D, Wang L, et al. (2002) Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res 69: 687-691.
26. Haynesworth SE, Baber MA, Caplan AI, (1996) Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 166: 585-592.
27. Liu Y, Dulchavsky DS, Gao X, Kwon D, Chopp M, et al. (2006) Wound repair by bone marrow stromal cells through growth factor production. J Surg Res 136: 336-341.
28. Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, et al. (1988) Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 81: 414-419.
29. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, et al. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443.
30. Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T, (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16: 1227-1235.
31. Roos F, Terrell TG, Godowski PJ, Chamow SM, Schwall RH, (1992) Reduction of alpha-naphthylisothiocyanate-induced hepatotoxicity by recombinant human hepatocyte growth factor. Endocrinology 131: 2540-2544.